Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoramidis open-label extension in symptomatic transthyretin amyloid cardiomyopathy after ATTRibute-CM
NL-OMON53804Phase 3Recruiting
- Sponsor
- Eidos Therapeutics
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of acoramidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Eidos Therapeutics. Primary endpoint: Safety and tolerability. Started Dec 2022; status: recruiting.
02
Drugs
acoramidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NL-OMON53804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53804.